People with type 2 diabetes who take SGLT-2 inhibitors tend to have lower fasting insulin levels than those using other diabetes drugs.

People with type 2 diabetes who take SGLT-2 inhibitors tend to have lower levels of a key inflammation marker called interleukin-6 than those taking other diabetes medications.

Type 2 diabetes patients taking SGLT-2 inhibitors have lower levels of uric acid in their blood than those on other diabetes medications.

A class of diabetes drugs (SGLT2 inhibitors) cuts hospitalizations for heart failure by a third and lowers death risk by nearly 40% — even before blood sugar improves — suggesting they protect the heart in ways beyond lowering sugar.